{
  "docId": "019de076-9d2b-76a8-843e-6686f2efe993",
  "docSlug": "264dd70dbc5f8f6fdd2a3dbf6f8c09b5",
  "documentTitle": "Exscientia | Investor Day Presentation Deck | 90 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 90,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9d2b-76a8-843e-6686f2efe993/6",
  "deckHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993",
  "deckJsonHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993.json",
  "deckAnchorHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.07,
        "y": 0.185
      },
      "kind": "list",
      "text": "Internal pipeline: Announced prioritisation of differentiated, high value, oncology targets; ELUCIDATE Phase 1/2 trial for CDK7 inhibitor (GTAEXS617) initiated in 1Q23; Completed IND enabling work for LSD1 inhibitor (EXS74539); New preclinical data for LSD1 and MALT1 inhibitors presented at ESMO in October 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3771892c-d151-4f23-90a4-06103a3880fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.53,
        "y": 0.65
      },
      "kind": "list",
      "text": "Technology updates: Presented data on automated kinase method to be applied at scale in future projects in 2H23; Novel automated discovery laboratory opened in Milton Park in mid-2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f0c4efe-6ad9-4214-93a0-0cee40a5bf98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.53,
        "y": 0.185
      },
      "kind": "list",
      "text": "Partnered programmes: AI drug discovery collaboration with Merck KGaA, Darmstadt, Germany signed in September 2023; New programme internally discovered by Exscientia added to Sanofi collaboration in 4Q23; First milestone achieved in Sanofi collaboration in 3Q23; Phase 1 study for EXS4318, a PKC-theta inhibitor designed by Exscientia and in-licensed by Bristol-Myers Squibb, was initiated in March 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c33ae185-329d-4af8-a7ab-bd4695f88074",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.07,
        "y": 0.65
      },
      "kind": "list",
      "text": "Precision medicine: EXCYTE-1 initiated in July 2023: Expanding the scope of precision medicine platform into solid tumours (ovarian cancer); Presented data supporting pipeline programmes’ potential combination and patient selection strategies at multiple medical meetings in 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3309817-d654-44e1-83ae-f5e885de4e0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "2023: Positioned us well for long-term growth",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da3e93a8-142e-4207-8aca-c4dcc6289f5c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "6bcf15c0-6c27-4ba1-b4d0-3bb40c9a9b7c",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Interest",
      "beatSlug": "aida-interest",
      "evidence": "The presentation deck generates interest by highlighting Exscientia's approach and achievements",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 4,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "118b0da0-1893-4824-ac01-9db0319b9704",
      "evidence": "The presentation deck presents a clear logic chain, connecting Exscientia's approach to its benefits",
      "position": 0,
      "objective": "To present Exscientia's approach to precision medicine",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 9,
      "from": 5,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "c3e30e9b-2a2e-4188-bb02-04eb888939d6",
      "evidence": "The presentation deck uses before-after comparisons to highlight the benefits of Exscientia's approach",
      "position": 1,
      "objective": "To highlight the benefits of Exscientia's approach",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}